Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KLRS

Kalaris Therapeutics Inc

Jun 12 • 12:49PM ET

4.45

+0.09 2.18 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: AARD AGEN CGTX CNTB GALT IMUX KZIA NTHI SPRO VRCA

| Held by: VTI VXF IWC DCOR DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.14	Insider Own	66.80%	Shs Outstand	22.99M	Perf Week	0.34%
Market Cap	97.24M	Forward P/E	-	EPS next Y	-1.54	Insider Trans	5.21%	Shs Float	7.90M	Perf Month	-7.76%
Enterprise Value	1.43M	PEG	-	EPS next Q	-0.47	Inst Own	21.26%	Short Float	10.15%	Perf Quarter	-48.62%
Income	-44.10M	P/S	-	EPS this Y	33.18%	Inst Trans	2.64%	Short Ratio	9.50	Perf Half Y	-41.15%
Sales	0.00M	P/B	1.49	EPS next Y	19.13%	ROA	-41.43%	Short Interest	0.80M	Perf YTD	-47.22%
Book/sh	2.98	P/C	1.00	EPS next 5Y	11.73%	ROE	-66.60%	52W High	11.88 -62.50%	Perf Year	61.41%
Cash/sh	4.45	P/FCF	-	EPS past 3/5Y	61.69% 45.59%	ROIC	-63.31%	52W Low	2.14 108.18%	Perf 3Y	-96.42%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.95% 7.87%	Perf 5Y	-99.12%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	73.91%	Oper. Margin	-	ATR (14)	0.37	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.14	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	40.48	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	12.14	EPS Q/Q	81.81%	SMA20	-5.92%	Beta	0.19	Target Price	19.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-16.92%	Rel Volume	0.26	Prev Close	4.36
Employees	20	LT Debt/Eq	0.02	Earnings	May 12 BMO	SMA200	-33.18%	Avg Volume	84.36K	Price	4.45
IPO	Jul 30, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	12.10% -	Trades		Volume	11,811	Change	2.18%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-26	Initiated	Wedbush	Outperform	$17
Apr-16-26	Initiated	Morgan Stanley	Overweight	$14
Dec-23-25	Initiated	Chardan Capital Markets	Buy	$19
Nov-03-25	Initiated	Citizens JMP	Mkt Outperform	$20
Sep-03-25	Initiated	Raymond James	Strong Buy	$23
Jul-23-25	Resumed	Piper Sandler	Neutral	$3
May-07-25	Initiated	Leerink Partners	Outperform	$20
Apr-08-25	Initiated	William Blair	Outperform

Today 08:00AM	Kalaris to Present at Clinical Trials at the Summit 2026 (GlobeNewswire)
May-14-26 09:45AM	Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls (The Fly) +8.07%
May-12-26 08:00AM	Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jan-28-26 04:05PM	Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting (GlobeNewswire)
Dec-17-25 05:59PM	Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement (GlobeNewswire) +20.32%
04:01PM	Loading…
04:01PM	Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naive Neovascular AMD (GlobeNewswire)
Nov-24-25 08:00AM	Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference (Newsfile) -7.99%
Nov-12-25 08:00AM	Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-03-25 07:30AM	Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer (GlobeNewswire)
Oct-30-25 08:00AM	Kalaris to Present at Stifel 2025 Annual Healthcare Conference (GlobeNewswire)
Sep-15-25 03:26PM	UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
08:00AM	Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
Sep-01-25 12:00PM	Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-13-25 08:00AM	Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -8.43%
Jun-02-25 08:00AM	Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference (GlobeNewswire)
11:03AM	Loading…
May-23-25 11:03AM	Kalaris to Participate at Stifel Ophthalmology Forum (GlobeNewswire)
May-14-25 08:00AM	Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-04-25 08:00AM	Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee (GlobeNewswire)
Mar-18-25 04:21PM	Kalaris Announces Closing of Merger with AlloVir (GlobeNewswire) +16.92%

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.

PresidentMr. Andrew Oxtoby

Ph.D.Dr. Srinivas Akkaraju M.D.

Co-Founder & DirectorDr. Michael Philip Dybbs Ph.D.

Independent Director & Co-FounderDr. Napoleone Ferrara M.D.

Chief Accounting Officer and Principal Accounting & Financial OfficerMr. Brett R. Hagen

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AKKARAJU SRINIVAS	Director	May 20 '26	Buy	4.83	244,300	1,179,969	2,224,147	May 22 07:47 PM
Hagen Brett R	Chief Accounting Officer	Mar 20 '26	Sale	6.72	1,915	12,869	0	Mar 23 04:05 PM
BRETT R R HAGEN	Officer	Mar 20 '26	Proposed Sale	6.72	1,915	12,869		Mar 20 04:07 PM
AKKARAJU SRINIVAS	Director	Dec 18 '25	Buy	10.42	479,847	5,000,006	1,979,847	Feb 17 08:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLRS

Kalaris Therapeutics Inc

Upgrade your Finviz experience